Co-Diagnostics

Co-Diagnostics

Biotechnology
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company’s technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.

$7.2M

Market Cap • 10/6/2026

2013

(13 years)

Founded

2017

(9 years ago)

IPO

NASDAQ

Listing Exchange

Flag of United States

United States

Country

Valuation

P/B

0,6

P/S

10

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2

EPS

—

Market Cap

Market Cap

7,2M

EV

5,3M

EV/Revenue

7,4

EV/EBITDA

-0,1

EV/EBIT

-0,1

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-251,8%

Total Yield

-251,8%

Payout

0%

Retained Earnings

-95,8M

Profitability

Gross Margin

43,5%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

2726,2%

Capex/Revenue

50,9%

Capex/D&A

37%

Capex/OCF

-1,4%

SBC/OCF

—

% PPE

22,6%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Revenue 5Y

-62,4%

Leverage

N.D./EBITDA

0

Debt/Equity

0%

Current Ratio

1,8

Quick Ratio

1,3

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium